Review Article
Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
Table 1
Summary of completed neoadjuvant chemotherapy trials.*
| Clinical trials | Design | Drugs | Population | pCR rate |
| Silver et al. [12] | Phase II single arm | Cisplatin × 4 | TNBC | 6/28 (21%) |
| Byrski et al. [13] | Retrosp. | All; CMF; AD; AC/FAC; cisplatin | BRCA1 mut. | All: 24/102 (24%) CMF: 1/14 (7%) AD: 2/25 (8%) AC/FAC: 11/51 (22%) Cisplatin: 10/12 (83%) |
| Bear et al. [14] | Phase III random. | Arm 1A: D × 4 → AC × 4 Arm 1B: D + X × 4 → AC × 4 Arm 1C: D + G × 4 cycles → Ac × 4 | HER2− | Arm 1A: 102/393 (26%) Arm 1B: 91/390 (23%) Arm 1C: 106/388 (27%) |
| Alba et al. [15] | Phase II random. | Arm A: EC × 4 cycles → D × 4 Arm B: EC × 4 cycles → D + Carbo × 4 | Basal-like | Arm A: 14/46 (30%) Arm B: 14/47 (30%) |
| Zelnak et al. [16] | Phase II random. | Arm A: D × 4 cycles → X × 4; Arm B: D + X × 8 cycles. | HER2− | Arm A: 2/25 (8%) Arm B: 3/26 (12%) Arm A/B (TNBC): 4/21 (19%) |
| Von Minckwitz et al. [17] Huober et al. [18] | Phase III random. | Arm 1 (responder): TAC × 4 Arm 2 (responder): TAC × 6 Arm 3 (nonresponder): TAC × 4 Arm 4 (nonresponder): VX × 4 | Any breast cancer | Arm 1–4 TNBC: 77/198 (39%) Non-TNBC: 22/147 (15%) |
| Baselga et al. [19] | Phase II single arm | Ixabepilone × 4 | Any breast cancer | TNBC: 11/42 (26%) Non-TNBC: 18/119 (15%) |
|
|
*TNBC: triple-negative breast cancer; pCR: pathological complete response; M: methotrexate; F: 5-fluorouracil; Retrosp.: retrospective study; T: paclitaxel; Carbo: carboplatin; D: docetaxel; C: cyclophosphamide; A: doxorubicin; E: epirubicin; X: capecitabine; G: gemcitabine; V: vinorelbine.
|